

**2012 Update of the CCS Guidelines for the Diagnosis and Treatment of Dyslipidemia
 for the Prevention of Cardiovascular Disease in the Adult
 Disclosures of Conflict of Interests**

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Primary Panel							
Todd Anderson	Yes	AstraZeneca, Merck, Roche, Sunovion	None	Abbott Vascular, Merck, Roche	None	None	None
Jean Grégoire	Yes	Abbott Vascular, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, sanofi-aventis, Schering Plough, Servier, Sunovion	None	AstraZeneca, Merck, Novartis, Roche, Servier, Cerennis	None	None	None
Andre Carpentier	None disclosed						
Patrick Couture	Yes	Merck, Hoffman-La Roche	None	None	None	None	None
Robert Dufour	Yes	AstraZeneca, Merck, Pfizer, Schering Plough, Abbott, Takeda, Sepracor Pharmaceuticals	None	Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, sanofi-aventis, Isis, Regeneron, Amgen, Genzyme, NovoNordisk	None	None	None
Gordon A. Francis	Yes	AstraZeneca, Merck, Roche, Sunovion	None	AstraZeneca, Pfizer, Acasti Pharma	None	None	None
Jacques Genest	Yes	AMGEN, AstraZeneca, Merck	None	AMGEN, Merck, Novartis	None	None	None
Steven Grover	Yes	AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer	None	Not Stated	None	Not Stated	None

2012 Update of the CCS Guidelines for the Diagnosis and Treatment of Dyslipidemia
for the Prevention of Cardiovascular Disease in the Adult
Disclosures of Conflict of Interests

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Milan Gupta	Yes	AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, sanofi-aventis, Servier	None	None	None	None	None
Rob Hegele	Yes	Abbott Vascular, AstraZeneca, Merck, Pfizer, Schering Plough, Sunovion	None	None	None	None	None
David Lau	Yes	Abbott Vascular, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, sanofi-aventis, Schering Plough	None	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Pfizer, sanofi-aventis	None	None	None
Lawrence Leitier	Yes	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis, Roche, sanofi-aventis, Servier, Novo Nordisk	None	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Roche, sanofi-aventis, Servier, Novo Nordisk	None	None	None
Eva Lonn	Yes	AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Roche, Servier	Not Stated	AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Roche, Schering Plough, Servier	Not Stated	None	None
GB John Mancini	Yes	AstraZeneca, GlaxoSmithKline, Merck, Roche, Servier	None	None	None	None	None

**2012 Update of the CCS Guidelines for the Diagnosis and Treatment of Dyslipidemia
 for the Prevention of Cardiovascular Disease in the Adult
 Disclosures of Conflict of Interests**

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Ruth McPherson	None disclosed						
Dominic Ng	Yes	GlaxoSmithKline, Merck, Roche, Schering Plough, Tribute Pharmaceutical	None	Abbott Vascular, GlaxoSmithKline	None	None	None
Glen Pearson	Yes	Roche, Otsuka	None	None	None	None	None
Paul Poirier	No	None	None	None	None	None	None
Allan Sniderman	Yes	Merck, Genzyme	None	None	None	None	None
James A. Stone	None disclosed						
Ehud Ur	Yes	Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Merck, Novartis, sanofi-aventis	None	Merck, sanofi-aventis	None	None	None
Richard Ward	Yes	Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Pfizer, sanofi-aventis, Schering Plough, Servier	None	Eli Lilly, Pfizer, sanofi-aventis	None	None	None
Gillian Yates	Yes	AstraZeneca	None	None	None	None	None
Secondary Panel							
Ranjani Krishnan Aiyar	No	None	None	None	None	None	None
Michael G Allan	No	None	None	None	None	None	None
Jean Bergeron	Yes	AstraZeneca, Merck, Roche, Sunovion	None	AstraZeneca, Merck, Novartis, Pfizer, Roche, sanofi-aventis, Schering Plough, AMGEN, Genzyme, Regeneron	None	None	None

**2012 Update of the CCS Guidelines for the Diagnosis and Treatment of Dyslipidemia
 for the Prevention of Cardiovascular Disease in the Adult
 Disclosures of Conflict of Interests**

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Alice Cheng	Yes	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Pfizer, Roche, sanofi-aventis, Schering Plough	None	AstraZeneca, Eli Lilly, sanofi-aventis	None	None	None
Ross Feldman	Yes	Boehringer Ingelheim, Janssen, Pfizer, Takeda	None	Servier	None	None	None
Wanda Firth	Yes	AstraZeneca	None	None	None	None	None
Jiri Frohilch	Yes	Merck, Pfizer, sanofi-aventis	None	AMGEN, Merck, sanofi-aventis	None	None	Yes, Merck
Geoffrey Lewis	No	None	None	None	None	None	None
Lynn Miller	No	None	None	None	None	None	None
Daniel Ngui	Yes	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Amgen	None	None	None	None	None
Sheldon Tobe	Yes	Abbott Vascular, AstraZeneca, Bayer, Bristol-Myers Squibb, Abbott Vascular, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Pfizer, sanofi-aventis, Otsuka, Takeda	None	AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novartis, Johnson & Johnson, Pfizer, Servier	None	None	None
Subodh Verma	Yes	AstraZeneca, Bayer, Boehringer Ingelheim, SmithGalxoKline, Merck, Novartis, Pfizer, Roche, Sorin	None	AstraZeneca	None	None	None

**2012 Update of the CCS Guidelines for the Diagnosis and Treatment of Dyslipidemia
 for the Prevention of Cardiovascular Disease in the Adult
 Disclosures of Conflict of Interests**

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Andrew Wong	Yes	Abbott Vascular, AstraZeneca, Bayer, Bristol-Myers Squibb, Servier	None	None	None	None	None
Vince Woo	Yes	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Metronic, Merck, Novartis, sanofi-aventis	None	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer	None	None	None